The global rheumatoid arthritis market size is expected to reach USD 33.30 billion by 2030, according to a new study by Polaris Market Research. The report “Rheumatoid Arthritis Market Share, Size, Trends, Industry Analysis Report, By Therapy (Cell Therapy, DMARD, Symptomatic Treatment, Intermediate Corticosteroid Therapies); By Distribution Channel; By Drug Type; By Region; Segment Forecast, 2022 - 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The market is being fueled by a rise in the number of arthritis and associated joint problems. Rheumatoid arthritis is on the rise as a result of the shift to an unhealthy lifestyle, rising metabolic disorders & age, family history of joint diseases, and increased obesity. As per the Centers for Disease Control and Prevention (CDC), millions of people in the US have severe pain due to arthritis each year. 15 million adults with arthritis report having severe joint pain as a result of their disease.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/rheumatoid-arthritis-market/request-for-sample
To strengthen their position in this market, manufacturers are concentrating on partnerships with other competitors. In January 2022, the Queen Mary University of London and Exagen Inc. announced a partnership and exclusive license agreement. The collaboration's main goal is to customize the choice of treatment agents for Rheumatoid Arthritis (RA) patients by developing and refining patent-pending personalized medicine techniques based on RNA expression patterns.
Both parties will work together to develop the patent-pending assays, which will eventually lead to the commercialization of cutting-edge molecular assays that divide patients into groups based on the expression of particular genes in synovial tissue biopsies. Thus, these factors are assisting the market growth over the forecast period.
Furthermore, in comparison to the general population, women have a higher risk of developing certain autoimmune illnesses. For instance, as per the Department of Health & Human Services (HHS) in the US, RA is the fourth-largest cause of disability among women in the US and are the eighth-leading cause of mortality for women between the ages of 15 and 64. The prevalence of rheumatoid arthritis (RA) in the US is high due to which the demand and adoption of treatment have increased. In rheumatoid arthritis (RA), the immune system attacks the joint.
The development of complex biologics, rising purchasing power, rising healthcare costs, and improved accessibility to high-quality medicines for middle-class and low-income families globally are all important causes. On the other hand, the global market is anticipated to grow swiftly and change the market picture due to improved treatment for early treatment and screening of rheumatoid arthritis. As a result, the global market for rheumatoid arthritis medications is seeing rapid growth, which is opening up attractive potential.
Rheumatoid Arthritis Market Report Highlights
Polaris Market Research has segmented the rheumatoid arthritis market report based on drug type, distribution channel, therapy, and region:
Rheumatoid Arthritis, Therapy Outlook (Revenue - USD Billion, 2018 - 2030)
Rheumatoid Arthritis, Distribution Channel Outlook (Revenue - USD Billion, 2018 - 2030)
Rheumatoid Arthritis, Drug Type Outlook (Revenue - USD Billion, 2018 - 2030)
Rheumatoid Arthritis, Regional Outlook (Revenue - USD Billion, 2018 - 2030)